imfinzi
astrazeneca ab - durvalumab - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).
plerixafor accord
accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - Ónæmisörvandi, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.
paclitaxel actavis innrennslisþykkni, lausn 6 mg/ml
actavis group ptc ehf. - paclitaxelum inn - innrennslisþykkni, lausn - 6 mg/ml
pedmarqsi
fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - Öll önnur lækningavörur - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.
berinert stungulyfs-/innrennslisstofn og leysir, lausn 500 a.e.
csl behring gmbh* - c1-hemill - stungulyfs-/innrennslisstofn og leysir, lausn - 500 a.e.
cefuroxim fresenius kabi stungulyfs-/innrennslisstofn, lausn 1500 mg
fresenius kabi ab - cefuroximum natríum - stungulyfs-/innrennslisstofn, lausn - 1500 mg
actilyse stungulyfs-/innrennslisstofn og leysir, lausn
boehringer ingelheim international gmbh* - alteplasum inn - stungulyfs-/innrennslisstofn og leysir, lausn
morphasol vet stungulyf, lausn 4 mg/ml
animedica gmbh* - butorphanolum tartrat - stungulyf, lausn - 4 mg/ml
berinert stungulyfsstofn og leysir, lausn 1500 a.e.
csl behring gmbh* - c1-hemill - stungulyfsstofn og leysir, lausn - 1500 a.e.
berinert stungulyfsstofn og leysir, lausn 2000 a.e.
csl behring gmbh* - c1-hemill - stungulyfsstofn og leysir, lausn - 2000 a.e.